PharmaLive

@pharmalive

The pharma industry’s destination for news & analysis, fostering a comprehensive & collaborative community for pharma & healthcare marketing professionals.

pharmalive.com Joined January 2009

378 Following 12K Followers 6.3K Posts

Latest posts 5

PharmaLive @pharmalive Oct 13

Lilly is putting its growing pile of GLP money to good use, with a run of 10 acquisitions since the beginning of this year.

Med Ad News @medadnews Oct 13

Congratulations to the Med Ad News 2026 Company of the Year, Eli Lilly pharmalive.com/company-of-the… #pharma @EliLillyandCo

View quoted post on X

PharmaLive @pharmalive Jul 28

Pharma people on the move: Summer 2026 roundup pharmalive.com/pharma-people-… #pharma #leadership

PharmaLive @pharmalive Jul 21

Novo Nordisk sues Lilly pharmalive.com/novo-nordisk-s… #lawsuit #GLP1 #weightloss #semaglutide

Novo Nordisk Inc. announced today that it has filed a lawsuit against Eli Lilly and Company and Lilly USA, LLC in the United States District Court for the District of New Jersey for multiple violations of federal and state false advertising and unfair competition laws, including under the Lanham Act.

PharmaLive @pharmalive Jun 11

Novo Nordisk flags IT security incident pharmalive.com/novo-nordisk-f… #cybersecurity #patients #data #clinicaltrials

Today Novo Nordisk issued an alert about an IT security incident that involved unauthorized access to internal IT systems. According to the company’s incident update, certain patient personal data from trial participation was compromised. The company stated that this information is not directly linked to any patients by name or other direct identifiers. “Information about identity would therefore require access to underlying information, identifying patients by name etc. This information was not exposed. We therefore do not consider the incident to enable any third party to identify participants in our clinical trials,” according to Novo Nordisk.

PharmaLive @pharmalive May 8

Johnson & Johnson launches “Generation Fine”, encourages patients to expect more from #depression treatment pharmalive.com/johnson-johnso… #JnJ #pharma #healthcare #marketing #patients #mentalhealth

Johnson & Johnson announced the launch of Generation Fine, a global campaign designed to challenge what it means to feel “fine” in depression care and empower patients to take the first step in moving beyond “good enough” by talking with their healthcare provider. Informed by a global survey of patients and healthcare providers spanning seven countries and four continents, the campaign reflects a troubling reality: nearly 4 in 5 patients living with major depressive disorder (MDD) don’t believe antidepressants will help them reach remission. Developed in collaboration with leading mental health advocates and drawing on the expertise of Mental Health America, Generation Fine highlights the unique challenges and experiences of people living with depression and provides valuable resources to support more productive conversations about their care—including the possibility of remission.